| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15171 R62272 |
Benevent - SNRI, 2023 | Gestational hypertension (blood pressure increase after the 20th week of amenorrhea), preeclampsia, eclampsia... - ICD or prescription | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SNRI only | 1.89 [1.13;3.18] | 19/163 4,940/107,843 | 4,959 | 163 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12526 R47189 |
Tran - SNRI (Controls exposed to TCA), 2022 | Preeclampsia/eclampsia (gestational hypertension and a co-presence of non-infectious proteinuria) | at least 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.19 [0.05;0.67] C excluded (control group) |
3/212 15/214 | 18 | 212 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12527 R47195 |
Tran - SNRI (Controls unexposed, NOS), 2022 | Preeclampsia/eclampsia (gestational hypertension and a co-presence of non-infectious proteinuria) | at least 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No Monotherapy: SNRI only | 0.52 [0.16;1.61] C | 3/212 2,582/95,376 | 2,585 | 212 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12538 R47227 |
Frayne - SNRI, 2021 | Hypertensive disorders in pregnancy (systolic blood pressure ≥ 140 mgHg, diastolic blood pressure ≥ 90 mmHg or with features diagnostic of preeclampsia) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 2.79 [1.33;5.83] | 8/31 -/255 | - | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12535 R47220 |
Yang - SNRI, 2021 | Preeclampsia (ICD-9 or ICD-10) from the 20th week of gestation. | 1st and 2nd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.96 [0.47;1.93] | -/338 -/2,832 | - | 338 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11745 R43126 |
Huybrechts - Duloxetine (Controls unexposed, NOS), 2020 | Pre-eclampsia (ICD-9 codes 642.4x, 642.5x, 642.6x, and 642.7x) | early pregnancy | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: no or not specified | 1.12 [0.96;1.31] | 171/3,059 48,599/1,447,644 | 48,770 | 3,059 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12531 R47208 |
Bernard - SNRI, 2019 | Preeclampsia (Gestational hypertension with proteinuria) or pre-existing hypertension and new or worsening proteinuria. | at least 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes Monotherapy: no or not specified | 6.46 [2.49;16.78] | -/57 -/6,502 | - | 57 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11822 R43432 |
Lupattelli - SNRI (Controls exposed to TCA), 2017 | Late‐onset preeclampsia (any severity, mild, and severe) (developing after GW 34) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.40 [0.06;2.54] C excluded (control group) |
3/75 2/21 | 5 | 75 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11823 R43433 |
Lupattelli - SNRI (Controls unexposed, sick), 2017 | Late‐onset preeclampsia (any severity, mild, and severe) (developing after GW 34) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No Monotherapy: SNRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.11 [0.35;3.56] C | 3/75 184/5,093 | 187 | 75 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12513 R47125 |
De Ocampo - SNRI, 2016 | Pre-eclampsia (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on two or more consecutive readings four or more hours apart with proteinuria of 0.3 g during 24 h or more after 20 weeks of gestation) | throughout pregnancy | prospective cohort | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SNRI only | 3.49 [0.76;16.09] | 2/21 123/3,119 | 125 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11810 R43414 |
Avalos - SNRI (Controls exposed to TCA), 2015 | Preeclampsia (ICD-9 codes occurring after 20 gestational weeks: 642.4, 642.5, 642.6, or 642.7) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
4.25 [0.80;22.54] C excluded (control group) |
5/72 2/116 | 7 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11811 R43415 |
Avalos - SNRI (Controls unexposed, disease free), 2015 | Preeclampsia (ICD-9 codes occurring after 20 gestational weeks: 642.4, 642.5, 642.6, or 642.7) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Monotherapy: SNRI only |
1.49 [0.57;3.90] excluded (control group) |
5/72 719/16,402 | 724 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11812 R43416 |
Avalos - SNRI (Controls unexposed, sick), 2015 | Preeclampsia (ICD-9 codes occurring after 20 gestational weeks: 642.4, 642.5, 642.6, or 642.7) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Monotherapy: SNRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.72 [0.67;4.43] C | 5/72 56/1,345 | 61 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11725 R43085 |
Palmsten a - SNRI (control exposed to TCA), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.81 [0.56;1.16] C excluded (control group) |
107/1,216 47/441 | 154 | 1,216 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11727 R43087 |
Palmsten a - SNRI (Controls unexposed, sick), 2013 | Preeclampsia and/or eclampsia (ICD-9 codes 642.4x–642.7x, after 140 gestational days and within 30 days after the delivery) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.52 [1.26;1.83] | 107/1,216 3,215/59,219 | 3,322 | 1,216 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11795 R43396 |
De Vera - SNRI, 2012 | Pregnancy-induced hypertension (gestational hypertension, pre-eclampsia, or eclampsia after the 20th week of gestation) | during pregnancy (anytime or not specified) | nested case control | unexposed (general population or NOS) | Adjustment: Yes Matched Monotherapy: SNRI only | 0.75 [0.17;3.25] | 2/- 1,214/- | 1,216 | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13369 R51608 |
Palmsten - SNRI (Controls exposed to TCA), 2012 | Preeclampsia (hypertension and proteinuria occurring after the 20th week of gestation) | 2nd trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.56 [0.28;1.13] C excluded (control group) |
23/408 14/146 | 37 | 408 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11726 R43086 |
Palmsten - SNRI (Controls unexposed, sick), 2012 | Preeclampsia (hypertension and proteinuria occurring after the 20th week of gestation) | 2nd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: SNRI only Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 1.95 [1.25;3.03] | 23/408 1,569/65,392 | 1,592 | 408 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 12 studies | 1.58 [1.22;2.06] | 62,817 | 5,652 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, NOS; 2: Controls unexposed, NOS; 3: Controls unexposed, sick; 4: Controls unexposed, sick; 5: Controls unexposed, sick; 6: Controls unexposed, sick;
Asymetry test p-value = 0.2662 (by Egger's regression)
slope=0.1909 (0.1347); intercept=0.8389 (0.7124); t=1.1777; p=0.2662
excluded 13369, 11725, 11810, 11811, 11822, 12526